Neonatal and Pediatric Candidemia: Results from Population-Based Active Laboratory Surveillance in Four US Locations, 2009-2015

Journal of the Pediatric Infectious Diseases Society

Volumn 7, Issue 3, 2018, Pages E78-E85

  Benedict, Kaitlin ^a   Roy, Monika ^a   Kabbani, Sarah ^b   Anderson, Evan J ^b   Farley, Monica M ^b   Harb, Sasha ^b   Harrison, Lee H ^c   Bonner, Lindsay ^c   Wadu, Vijitha Lahanda ^c   Marceaux, Kaytlyn ^c   Hollick, Rosemary ^c   Beldavs, Zintar G ^d   Zhang, Alexia Y ^d   Schaffner, William ^e   Graber, Caroline R ^e   Derado, Gordana ^a   Chiller, Tom M ^a   Lockhart, Shawn R ^a   Vallabhaneni, Snigdha ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d OREGON HEALTH AUTHORITY   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

candida; candidemia; children; infant; neonate

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE;

ADOLESCENT; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDEMIA; CHILD; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; INFANT; MALE; MICROBIOLOGY; NEWBORN; PREMATURITY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 85051592864     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piy009     Document Type: Article

References (52)

1. Magill SS, Edwards JR, Bamberg W, et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198-208.
2. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55: 1352-61.
3. Blyth CC, Chen SC, Slavin MA, et al; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123:1360-8.
4. Zaoutis T. Candidemia in children. Curr Med Res Opin 2010; 26:1761-8.
5. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149:2349-53.
6. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004; 17:638-80, table of contents.
7. Kaufman DA, Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol 2010; 37:611-28.
8. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
9. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1-50.
10. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One 2015; 10: e0120452.
11. Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008; 27:731-7.
12. Sarvikivi E, Lyytikäinen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43:2729-35.
13. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008; 121:703-10.
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA. 2008.
15. Deak E, Etienne KA, Lockhart SR, et al. Utility of a Luminex-based assay for multiplexed, rapid species identification of Candida isolates from an ongoing candidemia surveillance. Can J Microbiol 2010; 56:348-51.
16. Clinical and Laboratory Standards Institute. M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; 4th Informational Supplement. CLSI document MM18-A. Clinical and Laboratory Standards Institute, Wayne, PA.
17. National Center for Health Statistics. All-county birth data (2009-2015) as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program.
18. Chitnis AS, Magill SS, Edwards JR, et al. Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics 2012; 130: e46-52.
19. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117: 1680-7.
20. Schulman J, Stricof R, Stevens TP, et al. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics 2008; 127: 436-44.
21. Wirtschafter DD, Pettit J, Kurtin P, et al. A statewide quality improvement collaborative to reduce neonatal central line-associated blood stream infections. J Perinatol 2010; 30:170-81.
22. Bizzarro MJ, Sabo B, Noonan M, et al; Central Venous Catheter Initiative Committee. A quality improvement initiative to reduce central line-associated bloodstream infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2010; 31:241-8.
23. Aly H, Herson V, Duncan A, et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics 2005; 115:1513-8.
24. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660-6.
25. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005; 147:172-9.
26. Aydemir C, Oguz SS, Dizdar EA, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011; 96: F164-8.
27. Manzoni P, Stolfi I, Pugni L, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007; 356:2483-95.
28. Burwell LA, Kaufman D, Blakely J, et al. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics 2006; 118:e1019-26.
29. Blyth CC, Chen SC, Slavin MA, et al; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123:1360-8.
30. Fanfair RN AA, Farley M, et al. Racial disparities in candidemia: results from population-based surveillance in the United States, 2008-2010. International Conference on Antimicrobials and Chemotherapeutics (ICAAC). Chicago, September 17-20, 2011.
31. Crawford S, Joshi N, Boulet SL, et al; States Monitoring Assisted Reproductive Technology (SMART) Collaborative. Maternal racial and ethnic disparities in neonatal birth outcomes with and without assisted reproduction. Obstet Gynecol 2017; 129:1022-30.
32. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50:56-65.
33. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-23.
34. Blot S, Janssens R, Claeys G, et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006; 58:474-7.
35. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504-8.
36. Levy I, Rubin LG, Vasishtha S, et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998; 26:1086-8.
37. Rodriguez D, Almirante B, Park BJ, et al; Barcelona Candidemia Project Study Group. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006; 25:224-9.
38. Neu N, Malik M, Lunding A, et al. Epidemiology of candidemia at a children's hospital, 2002 to 2006. Pediatr Infect Dis J 2009; 28: 806-9.
39. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
40. Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-81.
41. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol 2013; 51: 841-8.
42. Poikonen E, Lyytikainen O, Anttila VJ, et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
43. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
44. Colombo AL, Nucci M, Park BJ, et al; Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44:2816-23.
45. Pappas PG, Rex JH, Lee J, et al; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-43.
46. Palazzi DL, Arrieta A, Castagnola E, et al. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 2014; 33:1294-6.
47. Pammi M, Holland L, Butler G, et al. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013; 32:e206-16.
48. Steinbach WJ, Roilides E, Berman D, et al; International Pediatric Fungal Network. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J 2012; 31:1252-7.
49. Vallabhaneni S, Cleveland AA, Farley MM, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008-2014. Open Forum Infect Dis 2015; 2: ofv163.
50. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr Blood Cancer 2012; 59:21-6.
51. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 2009; 147:125-8.
52. Fridkin S, Baggs J, Fagan R, et al; Centers for Disease Control and Prevention. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014; 63:194-200.